Stock ZALICUS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Zalicus Inc Share Price Nasdaq

Equities

US98887C1053

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Zalicus Inc
2018 Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
2018 Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q). CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2014 0 0.33 Sales 2015 0.7 58.53 Capitalization 75.33M 6.29B
Net income 2014 -41M -3.42B Net income 2015 -52M -4.34B EV / Sales 2014 14,77,02,94,750 x
Net cash position 2014 14.18M 1.18B Net cash position 2015 16.68M 1.39B EV / Sales 2015 8,36,58,631 x
P/E ratio 2014
-0.83 x
P/E ratio 2015
-1.35 x
Employees -
Yield 2014 *
-
Yield 2015
-
Free-Float 100%
More Fundamentals * Assessed data

Latest news about Zalicus Inc

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q). CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million. CI
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc. CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index CI
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations CI
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc.. CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million. CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes CI
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
More news

Company Profile

EPIRUS Biopharmaceuticals, Inc. is in bankruptcy.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPRSQ Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW